Document Detail

Zanamivir in the treatment of influenza.
MedLine Citation:
PMID:  12740002     Owner:  NLM     Status:  MEDLINE    
Influenza is a common illness, affecting many people every winter, with a considerable impact on mortality, hospital admissions, healthcare utilisation and sickness absence from work and school. Influenza management is currently focused on annual vaccinations for those in certain risk groups. Risk is determined by age and chronic illness, particularly diabetes, chronic respiratory and cardiac disease, and persons immunocompromised from disease or concomitant therapy. Amantadine (and in some countries, rimantadine is available but has not been widely used, because it is only effective against influenza A infections. The use of amantadines for treatment has been associated with the rapid emergence of resistant viruses capable of transmission, compromising its potential as a prophylactic, as well as a treatment. Side effects are well recognised and are a particular problem in the most vulnerable elderly populations, where dose restriction is necessary and prior knowledge of creatinine clearance desirable. The potential market for a new influenza treatment is large and the potential role of neuraminidase inhibitors in addressing this market has been covered in several review articles [1-4]. This review reports on the introduction of zanamivir (Relenza) to the market with particular reference to experience in the UK.
Douglas M Fleming
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  4     ISSN:  1465-6566     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2003 May 
Date Detail:
Created Date:  2003-05-12     Completed Date:  2003-07-22     Revised Date:  2008-04-14    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  799-805     Citation Subset:  IM    
Birmingham Research Unit of the Royal College of General Practitioners, Lordswood House, 54 Lordswood Road, Birmingham B17 9DB, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents* / pharmacokinetics,  pharmacology,  therapeutic use
Clinical Trials as Topic
Enzyme Inhibitors* / pharmacokinetics,  pharmacology,  therapeutic use
Influenza, Human* / drug therapy,  economics,  etiology
Neuraminidase / antagonists & inhibitors*
Risk Factors
Sialic Acids* / pharmacokinetics,  pharmacology,  therapeutic use
Reg. No./Substance:
0/Antiviral Agents; 0/Enzyme Inhibitors; 0/Guanidines; 0/Pyrans; 0/Sialic Acids; 139110-80-8/Zanamivir; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Safety and efficacy of tenecteplase in acute myocardial infarction.
Next Document:  Caspofungin: first approved agent in a new class of antifungals.